Activity and toxicity of pegylated liposomal doxorubicin in combination regimen (DRCOP) for patients >60 years old with untreated diffuse large B cell lymphoma (DLBCL): A phase II study
2008 ◽
Vol 26
(15_suppl)
◽
pp. 20505-20505